Novartis raises profit outlook as new medicines drive growth

Novartis: Novartis AG is a global pharmaceutical company headquartered in Switzerland that researches, develops, manufactures, markets, and sells innovative medicines across therapeutic areas including cardiovascular, immunology, oncology, neuroscience, and hematology. In the context of its third-quarter 2026 results announced on October 27, the company raised its full-year core operating income outlook as growth from newer priority brands and launches more than offset the impact of generic competition on former blockbuster Entresto. Recent pipeline updates include positive Phase III results for remibrutinib in relapsing multiple sclerosis along with label expansions and regulatory submissions for other candidates. Outlook Upgrade: The company upgraded its full-year core operating income guidance from a projected decline to a range of flat to low single-digit growth at constant currencies following solid third-quarter results. Pipeline Momentum: Novartis advanced multiple late-stage assets with positive Phase III results for remibrutinib in relapsing multiple sclerosis and additional regulatory approvals and submissions in recent weeks. Portfolio Transition: Strong performance from priority brands and new launches has enabled Novartis to demonstrate the replacement power of its business amid generic erosion on key products.